Erratum: Kinetics of hemagglutination-inhibiting antibodies following maternal influenza vaccination among Mothers with and those without HIV infection and their infants (Journal of Infectious Diseases (2015) 212:12 (1976-1987) DOI: 10.1093/infdis/jiv339);Kinetics of hemagglutination-inhibiting antibodies following maternal influenza vaccination among mothers with and those without HIV infection and their infants

Journal of Infectious Diseases

Volumn 212, Issue 12, 2015, Pages 1976-1987

  Nunes, Marta C ^a,b   Cutland, Clare L ^a,b   Dighero, Bonnie ^d,e   Bate, Janie ^d,e   Jones, Stephanie ^a,b   Hugo, Andrea ^a,b   Van Niekerk, Nadia ^a,b   Kuwanda, Locadiah ^a,b   Izu, Alane ^a,b   Weinberg, Adriana ^d,e   Madhi, Shabir A ^a,b,c  

^a NATIONAL RESEARCH FOUNDATION   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d University of Colorado Denver and Children s Hospital Colorado   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Immunogenicity; Influenza vaccine; Pregnancy; Transplacental antibody transfer

Indexed keywords

INFLUENZA VACCINE; PLACEBO; VIRUS ANTIBODY; INACTIVATED VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFANT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VIRUS STRAIN; BLOOD; COMPARATIVE STUDY; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; COHORT STUDIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84959432059     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiz293     Document Type: Erratum

References (37)

1. Neuzil KM, Coffey CS, Mitchel EF Jr, et al. Cardiopulmonary hospital-izations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003; 34:304-7.
2. Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148:1094-102.
3. Radwan HM, Cheeseman SH, Lai KK, et al. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000; 31:604-6.
4. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
5. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012-conclusions and recommendations. Wkly Epidemiol Rec 2012:201-16.
6. Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014; 371: 918-31.
7. Englund JA. The influence of maternal immunization on infant immune responses. J Comp Pathol 2007; 137(suppl 1):S16-9.
8. Puck JM, Glezen WP, Frank AL, et al. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J Infect Dis 1980; 142:844-9.
9. Steinhoff MC, Omer SB, Roy E, et al. Influenza immunization in pregnancy-antibody responses in mothers and infants. N Engl J Med 2010; 362:1644-6.
10. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359:1555-64.
11. Zuccotti G, Pogliani L, Pariani E, et al. Transplacental antibody transfer following maternal immunization with a pandemic 2009 influenza A (H1N1) MF59-adjuvanted vaccine. JAMA 2010; 304:2360-1.
12. Abzug MJ, Nachman SA, Muresan P, et al. Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis 2013; 56:1488-97.
13. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18:3040-9.
14. Miotti PG, Nelson KE, Dallabetta GA, et al. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262:779-83.
15. Nelson KE, Clements ML, Miotti P, et al. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988; 109:383-8.
16. Archer B, Cohen C, Naidoo D, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill 2009; 14:pii:19369.
17. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493-504.
18. Richardson K, Weinberg A. Reduced immunogenicity of influenza vaccines in HIV-infected compared with uninfected pregnant women is associated with regulatory T cells. AIDS 2011; 25:595-602.
19. Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenic-ity, and safety. Clin Infect Dis 2011; 52:128-37.
20. WHO. Recommended viruses for influenza vaccines for use in the 2011 southern hemisphere influenza season. http://www.who.int/influenza/vaccines/virus/recommendations/201009-Recommendation.pdf?ua=1. Accessed 31 January 2014.
21. Sanofi-pasteur. VAXIGRIP®. Inactivated influenza vaccine (Split Virion). http://products.sanofi.com.au/vaccines/VAXIGRIP-NZ-PI.pdf. Accessed 31 January 2014.
22. Weinberg A, Song LY, Walker R, et al. Anti-influenza serum and mu-cosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010; 55:189-96.
23. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377-81.
24. Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767-77.
25. Maltezou HC, Fotiou A, Antonakopoulos N, et al. Impact of postpar-tum influenza vaccination of mothers and household contacts in preventing febrile episodes, influenza-like illness, healthcare seeking, and administration of antibiotics in young infants during the 2012-2013 influenza season. Clin Infect Dis 2013; 57:1520-6.
26. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immuno-compromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46.
27. Yamanaka H, Teruya K, Tanaka M, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:167-73.
28. Fuller JD, Craven DE, Steger KA, et al. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999; 28:541-7.
29. Evison J, Farese S, Seitz M, et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompro-mised patients. Clin Infect Dis 2009; 48:1402-12.
30. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-23.
31. Abu Raya B, Srugo I, Kessel A, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels-a prospective study. Vaccine 2014; 32:5787-93.
32. Tsatsaris V, Capitant C, Schmitz T, et al. Maternal immune response and neonatal seroprotection from a single dose of a monovalent non-adjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial. Ann Intern Med 2011; 155:733-41.
33. Lin SY, Wu ET, Lin CH, et al. The safety and immunogenicity of triva-lent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan. PLoS One 2013; 8:e62983.
34. Jackson LA, Patel SM, Swamy GK, et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis 2011; 204:854-63.
35. Frasca D, Diaz A, Romero M, et al. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season. Immun Ageing 2013; 10:14.
36. Legrand FA, Nixon DF, Loo CP, et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One 2006; 1:e102.
37. Blanchard-Rohner G, Meier S, Bel M, et al. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn. Pe-diatr Infect Dis J 2013; 32:1374-80.